Expanding the Genotypic Spectrum of POMGNT1‐Related Muscle‐Eye‐Brain Disease: A Case Report
Molecular Genetics & Genomic Medicine · 2026
DOI: 10.1002/mgg3.70256 ↗Kurz gefasst
Fallbericht in der Zeitschrift Molecular Genetics & Genomic Medicine, 2026. Verfasst von Evripidis Pityrigkas und 6 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: N-Acetylglucosaminyltransferases, Walker-Warburg Syndrome. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Muscle‐Eye‐Brain disease (MEB) is a rare autosomal recessive dystroglycanopathy caused by defective glycosylation of α‐dystroglycan, leading to a multisystem disorder involving the central nervous system, skeletal muscle, and eyes. It represents an important cause of developmental and epileptic encephalopathy, with variable clinical severity and genetic heterogeneity, most commonly associated with variants in the POMGNT1 gene.
Methods
Clinical, neurophysiological, neuroimaging, histopathological, and genetic investigations were performed, including targeted next‐generation sequencing for congenital muscular dystrophy‐associated genes.
Results
The patient presented with early‐onset hypotonia, global developmental delay, progressive motor regression, intellectual disability, and ocular abnormalities. Epilepsy onset occurred in childhood and evolved into drug‐resistant epilepsy with status epilepticus in adulthood. Brain MRI revealed lissencephaly, ventriculomegaly, and brainstem and cerebellar hypoplasia. EEG demonstrated features consistent with epileptic encephalopathy. Genetic testing identified compound heterozygosity for the POMGNT1 variants c.1282C>T, p.(Gln428*) and c.793C>T, p.(Arg265Cys). Seizure control was eventually achieved with polytherapy including four antiseizure medications.
Conclusion
This case expands the genotypic and phenotypic spectrum of POMGNT1 ‐related MEB, highlighting the potential for severe epilepsy and status epilepticus in adulthood. It also underscores the importance of long‐term clinical follow‐up and suggests that aggressive antiseizure treatment may achieve seizure control even in advanced stages of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Genekor Medical S.A., Athens, Greece.
ORCID-Profile: Vasiliki Poulidou, Vasilios K Kimiskidis
Zitieren
APA
Pityrigkas, E., Poulidou, V., Kalampokini, S., Liouta, E., Pepe, G., Spilioti, M., & Kimiskidis, V. K. (2026). Expanding the Genotypic Spectrum of POMGNT1‐Related Muscle‐Eye‐Brain Disease: A Case Report. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70256
Vancouver
Pityrigkas E, Poulidou V, Kalampokini S, Liouta E, Pepe G, Spilioti M, et al. Expanding the Genotypic Spectrum of POMGNT1‐Related Muscle‐Eye‐Brain Disease: A Case Report. Molecular Genetics & Genomic Medicine. 2026. doi:10.1002/mgg3.70256
BibTeX
@article{Pityrigkas2026,
author = {Pityrigkas, Evripidis and Poulidou, Vasiliki and Kalampokini, Stefania and Liouta, Eleni and Pepe, Georgia and Spilioti, Martha and Kimiskidis, Vasilios K},
title = {Expanding the Genotypic Spectrum of POMGNT1‐Related Muscle‐Eye‐Brain Disease: A Case Report},
journal = {Molecular Genetics & Genomic Medicine},
year = {2026},
doi = {10.1002/mgg3.70256}
}
EUVIMED